<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121731</url>
  </required_header>
  <id_info>
    <org_study_id>NAHE001-CHC-01</org_study_id>
    <secondary_id>2009-012924-10</secondary_id>
    <nct_id>NCT01121731</nct_id>
  </id_info>
  <brief_title>A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C</brief_title>
  <official_title>Phase I/II, Multicenter, Randomized, Open,Active-Controlled, ClinicalTrial to Evaluate PK, PD, Safety and Tolerability Of Interferon Alfa 5, S.C. 3 Times Per Week, For 29 Days, To Treat-Experienced Pat. With Genotype-1 Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Digna Biotech S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Digna Biotech S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general aim of this study is to determine if 3 MIU of IFN-α5 in monotherapy, and 1,5 MIU&#xD;
      of IFN-α5 combined with 1,5 MIU of IFN- α2b, are safe dose levels as well as to investigate&#xD;
      the antiviral efficacy and pharmacodynamics (PD) of such doses and drugs in&#xD;
      treatment-experienced HCV patients with genotype 1 chronic infection, after 29 days of&#xD;
      treatment. It is also intended to determine pharmacokinetics (PK) of the safe dose achieved&#xD;
      of IFN-α5 in monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safe dose level</measure>
    <time_frame>29 days of treatment</time_frame>
    <description>PRIMARY ENDPOINTS OF PHASE I&#xD;
To determine if 3 MIU of IFN-α5 are well tolerated and if not, to find a safe dose level for IFN-α5.&#xD;
To determine if 1.5 MIU of IFN-α5 in combination with 1.5 MIU of IFN-α2b (IFN-α5 + IFN-α2b) are well tolerated and if not, to find a safe dose level for the combination of IFN-α5 and IFN-α2b.&#xD;
PRIMARY ENDPOINTS OF PHASE II&#xD;
To analyze IFN-α5 preliminary antiviral efficacy at the dose of 3 MIU, or the safe dose level identified in Phase I.&#xD;
Primary safety endpoints: Occurrence of AE (classified into mild, moderate and severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic and pharmacokinetic parameters</measure>
    <time_frame>29 days of treatment</time_frame>
    <description>SECONDARY ENDPOINTS OF PHASE I&#xD;
To obtain pharmacokinetic parameters of IFN-α5 in monotherapy after single and multiple dose administration&#xD;
To obtain pharmacodynamic parameters of IFN-α5 in monotherapy and in combination with IFN-α2b&#xD;
SECONDARY ENDPOINTS OF PHASE II&#xD;
To analyze IFN-α5 + IFN-α2b preliminary antiviral efficacy and comparison between IFN-α5 in monotherapy, IFN-α5 + IFN-α2b and IFN-α2b in monotherapy.&#xD;
To obtain pharmacodynamic parameters after treatment with IFN-α5, IFN-α5 + IFN-α2b or IFN-α2b.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Hepatitis C Virus Infection</condition>
  <condition>Genotype 1</condition>
  <condition>Treatment-Experienced Patients</condition>
  <condition>Relapses</condition>
  <arm_group>
    <arm_group_label>Interferon α-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon α-5 plus Interferon α-2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon α-2b (INTRON® A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon α-5</intervention_name>
    <description>3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.</description>
    <arm_group_label>Interferon α-5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-α5 plus Interferon-α 2b</intervention_name>
    <description>Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.</description>
    <arm_group_label>Interferon α-5 plus Interferon α-2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon α-2b (INTRON® A)</intervention_name>
    <description>3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.</description>
    <arm_group_label>Interferon α-2b (INTRON® A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged ≥18 years old,&#xD;
&#xD;
          2. With chronic hepatitis C (CHC) infection diagnosed by seropositivity for anti-HCV&#xD;
             antibodies or detectable HCV-RNA, at least 6 months prior to screening.&#xD;
&#xD;
          3. Patients with CHC infection of genotype 1 (1a, 1b or mixed 1a/1b)&#xD;
&#xD;
          4. Defined as relapsers: those CHC patients who had achieved virologic response (HCV-RNA&#xD;
             non detectable) at any time during the standard care of treatment for CHC with IFN-α2&#xD;
             or PegIFN-α2 + ribavirin, and maintained it trough the end of treatment at week 48&#xD;
             weeks, but HCV-RNA detection occurs before 6 months post-treatment.&#xD;
&#xD;
          5. In whom liver cirrhosis has been ruled out through fibro-scan or liver biopsy within&#xD;
             24 months prior to study enrolment.&#xD;
&#xD;
          6. With a serum HCV viral load ≥ 100.000 IU/mL at screening&#xD;
&#xD;
          7. With alanine-aminotransferase (ALT) and aspartate-aminotransferase (AST) serum&#xD;
             measurements at screening less than 5 times of their upper limits of normal (ULN)&#xD;
&#xD;
          8. With a body mass index (BMI) of at least 18 kg/m2, but not exceeding 36 kg/m2.&#xD;
&#xD;
          9. For female subjects with childbearing potential: use of a known highly effective&#xD;
             method of birth control&#xD;
&#xD;
         10. For male subjects with partners of child bearing potential: use of appropriate&#xD;
             contraceptive methods.&#xD;
&#xD;
         11. Is able to effectively communicate with the investigator and other testing center&#xD;
             personnel.&#xD;
&#xD;
         12. Is able to participate and willing to give written informed consent and comply with&#xD;
             the study restrictions.&#xD;
&#xD;
        Exclusion Criteria(principal):&#xD;
&#xD;
          1. Hepatitis C infection of genotype 2, 3 or 4 or any mixed genotype (1/2, 1/3 and 1/4).&#xD;
&#xD;
          2. A positive ELISA for HIV-1 or HIV-2.&#xD;
&#xD;
          3. Hepatitis B virus (HBV) infection based on the presence of HBsAg.&#xD;
&#xD;
          4. Hepatitis A virus (HAV) infection based on the presence of antiHAV-IgM. (AM 4)Criteria&#xD;
             deleted&#xD;
&#xD;
          5. Decompensated liver disease, or history of decompensated liver disease.&#xD;
&#xD;
          6. History or other evidence of a medical condition associated with decompensated renal,&#xD;
             immunologically mediated, chronic pulmonary, cardiac, thyroid, severe retinopathy,&#xD;
             severe psychiatric, organ transplantation, cancer, seizure disorder or pancreatitis&#xD;
             diseases.&#xD;
&#xD;
          7. An active or suspected malignancy or history of malignancy within the last five years.&#xD;
&#xD;
          8. Patients with a documented drug and alcohol addiction free history of at least 12&#xD;
             months who are, in the opinion of the investigator unlikely to relapse, may be&#xD;
             enrolled in the study.&#xD;
&#xD;
          9. Positive results for drug abuse at screening.Occasional use of cannabis previously to&#xD;
             randomization is not an exclusion criteria -under investigator team criteria-. The&#xD;
             patient should be advised of abstinence during the trial (AM 6)&#xD;
&#xD;
         10. Haemoglobin &lt;12.0g/dL for women, and &lt;13.0g/dL for men at screening.&#xD;
&#xD;
         11. White blood cell count &lt;2000 cells/mm3 at screening.&#xD;
&#xD;
         12. Absolute neutrophil count &lt;1500 cells/mm3 at screening.&#xD;
&#xD;
         13. Platelet count &lt;100.000 cells/mm3 at screening.&#xD;
&#xD;
         14. ALT and AST levels ≥ 5 xULN at screening.&#xD;
&#xD;
         15. Prothrombin time INR prolonged to 1.5xULN at screening.&#xD;
&#xD;
         16. TSH an T4 outside normal limits and not adequately controlled thyroid function at&#xD;
             screening.&#xD;
&#xD;
         17. Poorly controlled diabetes mellitus as evidenced by HbA1c &gt;7.5% at screening.&#xD;
&#xD;
         18. Alfa-fetoprotein value &gt;100ng/mL at screening.&#xD;
&#xD;
         19. Total bilirubin &gt;1.5xULN with ratio of direct/indirect &gt;1, at screening unless&#xD;
             predominantly conjugated and reflecting Gilbert's disease&#xD;
&#xD;
         20. Estimated creatinine clearance of 30 mL/minute or less at screening.&#xD;
&#xD;
         21. Women who are confirmed to be pregnant&#xD;
&#xD;
         22. People with known hypersensitivity to any ingredient of the investigational agents&#xD;
&#xD;
         23. Patients who are at risk of bleeding.&#xD;
&#xD;
         24. Haemoglobinopathy&#xD;
&#xD;
         25. Screening ECG QTc value ≥ 450ms and/or clinically significant ECG findings.&#xD;
&#xD;
         26. History of clinically significant drug allergies.&#xD;
&#xD;
         27. Participation in a clinical study with an investigational drug, biologic, or device&#xD;
             within 3 months prior to anticipated dose administration.&#xD;
&#xD;
         28. Any chronic viral (including HSV), bacterial, mycobacterial, fungal, parasitic, or&#xD;
             protozoal infection.&#xD;
&#xD;
         29. Requirement for chronic systemic corticosteroids.&#xD;
&#xD;
         30. Receiving systemic antivirals, hematopoietic growth factor, or immunomodulatory&#xD;
             treatment within 30 days prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús Prieto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universidad de Navarra. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre 013</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 004</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 005</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 008</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 011</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 014</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 015</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 002</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 003</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 006</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 009</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 016</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 001</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 012</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre 010</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C Viral Infection</keyword>
  <keyword>Interferon alfa-5</keyword>
  <keyword>Interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 23, 2014</submitted>
    <returned>May 21, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

